TARS Tarsus Pharmaceuticals
Tarsus Pharmaceuticals earnings company data as of 4:46 AM ET 10/24
Limited consensus data for this ticker (thin coverage or data-plan limits).
Dates may be company-announced rather than sell-side consensus.
Calendar and recent prints remain the primary lens when available.
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 3 Nov | EPS | — | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by TARS's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- $847K sold by 1 insider under 10b5-1 plans
-
William J Link PHD DirectorPlanned sale$847K 10,446 shares at $81.07 100% of stakeTraded Dec 15, 2025 Filed Dec 17, 2025
Also filed in the last 12 months, not counted as buying or selling: 57 sales to cover taxes, 20 option exercises, and 3 gifts.
SEC filings
Recent issuer filings from EDGAR, 15 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K/A | 9.01 | Filing Doc | |
| 8-K | 2.01,8.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 1.01,3.02,8.01,9.01 | Filing Doc | |
| 8-K | 1.01,3.02,8.01,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 5.02 | Filing Doc | |
| 8-K | 1.01,3.02,8.01,9.01 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.